A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension

Timeline

Start

2026-02-06

Primary completion

2029-03-27

Completion

2029-03-27

Drugs

Indications